Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | CTSV | O60911 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752652 | 0.91 | CTSL (0.38) | CTSLPYGLCNR2PTGER4CTSV | |
| SCHEMBL5752403 | 0.88 | CTSL (0.36) | CTSLCNR2PTGER4PSMB5 | |
| SCHEMBL5752534 | 0.87 | CTSL (0.38) | CTSLCNR2PTGER4CTSVCTSS | |
| SCHEMBL5751398 | 0.85 | CNR1 (0.37) | CTSLCNR2 | |
| SCHEMBL5751663 | 0.83 | CTSL (0.39) | CTSLPTGER4CTSVCTSSBACE1 | |
| SCHEMBL5748991 | 0.83 | UGCG (0.36) | CTSLCNR2PTGER4 | |
| SCHEMBL2139706 | 0.82 | OPRM1 (0.37) | PTGER4BACE1 | |
| SCHEMBL5750071 | 0.80 | CTSL (0.37) | CTSLCNR2PTGER4 | |
| SCHEMBL5752146 | 0.80 | CTSL (0.37) | CTSLMAPK1PTGER4CTSVCTSS | |
| SCHEMBL5752397 | 0.79 | SMO (0.35) | CTSLPYGLPTGER4CTSVCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | CTSL 2240/4885MAPK1 2140/4885PYGL 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.